Q-omics provides the consensus-scored BEST3 profile across patient tissues and cancer cell-line models. BEST3 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, BEST3 is differentially expressed in 12, with the highest sampling consensus in KIRP. Additionally, BEST3 RNA expression shows 13,314 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LUAD, KIRP, and TGCT as cancer lineages where BEST3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BEST3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BEST3 survival associations across molecular data types. BEST3 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BEST3 RNA expression–survival associations across cancer types. High BEST3 expression shows unfavorable associations in LUAD, THCA, MESO and HNSC, but favorable associations in ACC and LGG. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for BEST3 RNA expression.
This table summarizes BEST3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for BEST3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BEST3 shows lower tumor expression in KICH and HNSC and higher tumor expression in KIRP, KIRC, COAD and UCEC. The KIRP box plot shows higher BEST3 RNA expression in tumor versus normal tissue (log2 FC = +0.725, t-test p < 0.001).
This table shows molecular features associated with BEST3 in patient tissues and cancer cell lines. In patient samples, BEST3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, BEST3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and LUNG_SCLC.
